Fulcrum Therapeutics, Inc.SEC Filings
|
|
All SEC filings by Fulcrum Therapeutics, Inc. (FULC) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Jul 30, 2026 | |
| ARS | Annual report to shareholders | Apr 30, 2026 | ||
| 10-Q | Quarterly report | View Diff | Apr 27, 2026 | |
| 10-K | Annual report | View Diff | Feb 24, 2026 | |
| 10-Q | Quarterly report | View Diff | Oct 29, 2025 | |
| 10-Q | Quarterly report | View Diff | Jul 29, 2025 | |
| 10-Q | Quarterly report | View Diff | May 1, 2025 | |
| ARS | Annual report to shareholders | Apr 30, 2025 | ||
| 10-K | Annual report | View Diff | Feb 25, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 13, 2024 |
Events
| 8-K | Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement To | Aug 17, 2026 | ||
| 8-K | Current report | Aug 10, 2026 | ||
| 8-K | Current report | Jun 25, 2026 | ||
| 8-K | Current report | Jun 11, 2026 | ||
| 8-K | Current report | Jun 4, 2026 | ||
| 8-K | Current report | Jun 1, 2026 | ||
| 8-K | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results | Apr 27, 2026 | ||
| 8-K | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results | Feb 24, 2026 | ||
| 8-K | Results of Operations and Financial Condition | Jan 12, 2026 | ||
| 8-K | Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants | Dec 10, 2025 |
Registrations and Prospectuses
| S-4/A | Registration of securities issued in business combination transactions | View Diff | 5h ago | |
| S-4 | Registration of securities issued in business combination transactions | Sep 1, 2026 | ||
| 425 | Business combination disclosure | Aug 17, 2026 | ||
| 425 | Business combination disclosure | Aug 17, 2026 | ||
| 425 | Business combination disclosure | Aug 17, 2026 | ||
| 425 | Business combination disclosure | Aug 17, 2026 | ||
| 425 | Business combination disclosure | Aug 17, 2026 | ||
| S-8 | Registration of securities for employees | Feb 24, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | Dec 10, 2025 | ||
| FWP | Free writing prospectus | Dec 10, 2025 |
Proxies
| DEFA14A | Annual Meeting of Shareholders | Apr 30, 2026 | ||
| DEF 14A | Annual Meeting of Shareholders | View Diff | Apr 30, 2026 | |
| DEFR14A | Revised proxy | May 7, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 30, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 30, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Apr 19, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 19, 2024 | |
| DEFA14A | Additional proxy soliciting materials | Apr 28, 2023 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 28, 2023 | |
| PRE 14A | Preliminary proxy | Apr 18, 2023 |
Other
| EFFECT | Notice of effectiveness | Apr 26, 2024 | ||
| CORRESP | Correspondence with SEC | Apr 24, 2024 | ||
| UPLOAD | Letter from SEC | Mar 1, 2024 | ||
| EFFECT | Notice of effectiveness | Apr 29, 2022 | ||
| SEC STAFF | SEC staff action: Order | Mar 22, 2021 | ||
| SEC STAFF | SEC staff action: Order | Feb 22, 2021 | ||
| EFFECT | Notice of effectiveness | Aug 18, 2020 | ||
| EFFECT | Notice of effectiveness | Aug 13, 2020 | ||
| CORRESP | Correspondence with SEC | Aug 13, 2020 | ||
| UPLOAD | Letter from SEC | Aug 12, 2020 |
Ownership
| 144 | Notice of proposed sale of securities | Sep 2, 2026 | ||
| SC 13G/A | Ra Capital Management, L.p. Updates Stake in Fulcrum Therapeutics, Inc. | Aug 14, 2026 | ||
| SC 13G | Nantahala Capital Management, Llc Acquires Stake in Fulcrum Therapeutics, Inc. | Aug 14, 2026 | ||
| SC 13G/A | Montanova Capital, Llc Updates 5.5% Stake in Fulcrum Therapeutics, Inc. | Aug 14, 2026 | ||
| SC 13G/A | Tcg Crossover Gp Ii, Llc Updates Stake in Fulcrum Therapeutics, Inc. | Aug 14, 2026 | ||
| SC 13G | Bank of America Corp Acquires Stake in Fulcrum Therapeutics, Inc. | Aug 3, 2026 | ||
| SC 13G/A | Blackrock, Inc. Updates 7.2% Stake in Fulcrum Therapeutics, Inc. | Jul 28, 2026 | ||
| 4 | Tang Kevin | Jul 20, 2026 | ||
| SC 13G | Blackrock Portfolio Management Llc Acquires Stake in Fulcrum Therapeutics, Inc. | Jul 17, 2026 | ||
| SC 13G/A | Tang Capital Management Llc Updates Stake in Fulcrum Therapeutics, Inc. | Jul 15, 2026 |